Early cancer detection has always been one of the most compelling opportunities in healthcare. The problem is enormous, the potential impact is substantial, and the economics of diagnosing cancer earlier can be transformative.

For years, however, the challenge for GRAIL $GRAL ( ▼ 1.49% ) has been proving that Galleri could move from an impressive technology into a widely adopted medical product. That story has now taken an important step forward.

GRAIL's Galleri multi-cancer early detection test received a favorable vote from the FDA's advisory committee in late September, with the committee supporting the test across safety, effectiveness, and overall benefit-risk considerations. The FDA still has to make the final decision, but the AdCom outcome materially reduces one of the biggest uncertainties surrounding the investment thesis.

This is particularly important because my bullish thesis on GRAIL has never depended on Galleri immediately becoming a massive commercial product. The opportunity has always been about what happens if the company clears the regulatory hurdle and gains access to much broader reimbursement and adoption. Let’s take a deeper dive into one of the most exciting names in healthcare.